Hematologic Malignancy
B-Cell Non-Hodgkin Lymphoma
CI-CAN-00000471Explore in graph →
Hematologic1,757 active trials43 approved drugs73 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000471Explore in graph →
Clinical trials
6,180 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (954)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05013437 | Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT (Autologous Hematopoietic Cell Transplant) for Multiple Myeloma(AHCT) | withdrawn | Early Phase 1 | 0 | Koen van BesienOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT03591614 | Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma | withdrawn | Early Phase 1 | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 18, 2023 |
| clinicaltrials |
| NCT04984330 | Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease(STARR) | withdrawn | Early Phase 1 | 0 | Weill Medical College of Cornell UniversityOTHER | 1 | Nov 17, 2022 | clinicaltrials |
| NCT02971410 | Simvastatin in Overcoming Chemotherapy Resistance in Patients With Relapsed or Refractory Multiple Myeloma | withdrawn | Early Phase 1 | 0 | Wake Forest University Health SciencesOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT02447055 | Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma | withdrawn | Early Phase 1 | 0 | Washington University School of MedicineOTHER | 0 | Jul 12, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Apr 2, 2024source: clinicaltrials